//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
New results from the ALASCCA prospective randomised controlled trial showing daily #aspirin reduces colorectal cancer recurrence by ~50% in patients with PIK3CA or related mutations. Findings extend benefits of aspirin beyond Lynch syndrome cancers to nearly 40% of CRCs ascopubs.org/doi/10.1200/...
ascopubs.org
Low-dose aspirin to reduce recurrence rate in colorectal cancer patients with PI3K pathway alterations: 3-year results from a randomized placebo-controlled trial.
LBA125Background: Colorectal cancer (CRC) affects 1.9 million individuals globally each year. Among patients with stage II-III CRC, 20-40% develop metastatic disease. Aspirin lowers the incidence of a...
Mar 25, 2025
Roychoudhuri Lab